Kymera Therapeutics, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Kymera Therapeutics completed enrollment in KT-621 BROADEN2 Phase 2b atopic dermatitis trial six months ahead of schedule, accelerating year-end 2026 data readout (previously mid-2027) and enabling Phase 3 initiation by mid-2027. The company recognized $65M collaboration revenue in Q2 2026 ($45M Gilead option exercise for KT-200, $20M Sanofi milestone for KT-485 Phase 1 initiation); net loss was $61.2M vs. $76.6M year-ago. Cash position stands at $1.5B as of June 30, 2026, providing runway into 2029.
Why this rating
Enrollment acceleration and dual partnership milestones materially advance lead program timeline; $65M revenue is ~2.8% of $2.3B market cap. Meaningful near-term catalyst pull-forward reduces clinical risk.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.